#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Stroke-associated pneumonia ( SAP ) is defined as a spectrum of lower respiratory infections within the first 7 days of stroke onset .
2-1	16-33	Stroke-associated	abstract[2]	new[2]	appos	2-4[0_2]
2-2	34-43	pneumonia	abstract[2]	new[2]	_	_
2-3	44-45	(	_	_	_	_
2-4	46-49	SAP	abstract	giv	ana	3-1
2-5	50-51	)	_	_	_	_
2-6	52-54	is	_	_	_	_
2-7	55-62	defined	_	_	_	_
2-8	63-65	as	_	_	_	_
2-9	66-67	a	_	_	_	_
2-10	68-76	spectrum	_	_	_	_
2-11	77-79	of	_	_	_	_
2-12	80-85	lower	abstract[4]	new[4]	coref	3-5[10_4]
2-13	86-97	respiratory	abstract[4]	new[4]	_	_
2-14	98-108	infections	abstract[4]	new[4]	_	_
2-15	109-115	within	_	_	_	_
2-16	116-119	the	time[5]	new[5]	_	_
2-17	120-125	first	time[5]	new[5]	_	_
2-18	126-127	7	time[5]	new[5]	_	_
2-19	128-132	days	time[5]	new[5]	_	_
2-20	133-135	of	time[5]	new[5]	_	_
2-21	136-142	stroke	time[5]|event|event[7]	new[5]|new|new[7]	coref	5-1
2-22	143-148	onset	time[5]|event[7]	new[5]|new[7]	_	_
2-23	149-150	.	_	_	_	_

#Text=It is one of the most frequent post-stroke infections affecting 14 % of patients and is associated with a three-fold increase in hospital mortality , prolonged hospital stay and poor functional outcomes .
3-1	151-153	It	abstract	giv	coref	4-4
3-2	154-156	is	_	_	_	_
3-3	157-160	one	abstract[9]	new[9]	_	_
3-4	161-163	of	abstract[9]	new[9]	_	_
3-5	164-167	the	abstract[9]|abstract[10]	new[9]|giv[10]	_	_
3-6	168-172	most	abstract[9]|abstract[10]	new[9]|giv[10]	_	_
3-7	173-181	frequent	abstract[9]|abstract[10]	new[9]|giv[10]	_	_
3-8	182-193	post-stroke	abstract[9]|abstract[10]	new[9]|giv[10]	_	_
3-9	194-204	infections	abstract[9]|abstract[10]	new[9]|giv[10]	_	_
3-10	205-214	affecting	_	_	_	_
3-11	215-217	14	quantity[11]	new[11]	_	_
3-12	218-219	%	quantity[11]	new[11]	_	_
3-13	220-222	of	quantity[11]	new[11]	_	_
3-14	223-231	patients	quantity[11]|person	new[11]|new	coref	6-9[36_0]
3-15	232-235	and	_	_	_	_
3-16	236-238	is	_	_	_	_
3-17	239-249	associated	_	_	_	_
3-18	250-254	with	_	_	_	_
3-19	255-256	a	abstract[13]	new[13]	_	_
3-20	257-267	three-fold	abstract[13]	new[13]	_	_
3-21	268-276	increase	abstract[13]	new[13]	_	_
3-22	277-279	in	abstract[13]	new[13]	_	_
3-23	280-288	hospital	abstract[13]|place|abstract[15]	new[13]|new|new[15]	coref	3-27
3-24	289-298	mortality	abstract[13]|abstract[15]	new[13]|new[15]	_	_
3-25	299-300	,	_	_	_	_
3-26	301-310	prolonged	_	_	_	_
3-27	311-319	hospital	place|time[17]	giv|new[17]	coref	7-24
3-28	320-324	stay	time[17]	new[17]	_	_
3-29	325-328	and	_	_	_	_
3-30	329-333	poor	event[18]	new[18]	coref	14-16[136_18]
3-31	334-344	functional	event[18]	new[18]	_	_
3-32	345-353	outcomes	event[18]	new[18]	_	_
3-33	354-355	.	_	_	_	_

#Text=The pathophysiology of SAP is multifactorial .
4-1	356-359	The	abstract[19]	new[19]	_	_
4-2	360-375	pathophysiology	abstract[19]	new[19]	_	_
4-3	376-378	of	abstract[19]	new[19]	_	_
4-4	379-382	SAP	abstract[19]|abstract	new[19]|giv	coref	5-22
4-5	383-385	is	_	_	_	_
4-6	386-400	multifactorial	_	_	_	_
4-7	401-402	.	_	_	_	_

#Text=Stroke induced immunosuppression , aspiration of oropharyngeal secretions and stomach contents , related to impaired consciousness and dysphagia increase vulnerability to SAP in the acute phase .
5-1	403-409	Stroke	abstract	giv	coref	6-9
5-2	410-417	induced	_	_	_	_
5-3	418-435	immunosuppression	abstract|abstract[23]	new|new[23]	coref|coref	16-15[148_0]|16-15[149_23]
5-4	436-437	,	abstract[23]	new[23]	_	_
5-5	438-448	aspiration	abstract[23]|abstract[24]	new[23]|new[24]	coref	6-20[41_24]
5-6	449-451	of	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-7	452-465	oropharyngeal	abstract[23]|abstract[24]|substance[25]	new[23]|new[24]|new[25]	_	_
5-8	466-476	secretions	abstract[23]|abstract[24]|substance[25]	new[23]|new[24]|new[25]	_	_
5-9	477-480	and	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-10	481-488	stomach	abstract[23]|abstract[24]|abstract|object[27]	new[23]|new[24]|new|new[27]	_	_
5-11	489-497	contents	abstract[23]|abstract[24]|object[27]	new[23]|new[24]|new[27]	_	_
5-12	498-499	,	_	_	_	_
5-13	500-507	related	_	_	_	_
5-14	508-510	to	_	_	_	_
5-15	511-519	impaired	abstract[28]	new[28]	_	_
5-16	520-533	consciousness	abstract[28]	new[28]	_	_
5-17	534-537	and	_	_	_	_
5-18	538-547	dysphagia	abstract[29]	new[29]	_	_
5-19	548-556	increase	abstract[29]	new[29]	_	_
5-20	557-570	vulnerability	abstract[29]	new[29]	_	_
5-21	571-573	to	abstract[29]	new[29]	_	_
5-22	574-577	SAP	abstract[29]|abstract	new[29]|giv	coref	6-15
5-23	578-580	in	abstract[29]	new[29]	_	_
5-24	581-584	the	abstract[29]|abstract[31]	new[29]|new[31]	_	_
5-25	585-590	acute	abstract[29]|abstract[31]	new[29]|new[31]	_	_
5-26	591-596	phase	abstract[29]|abstract[31]	new[29]|new[31]	_	_
5-27	597-598	.	_	_	_	_

#Text=Dysphagia occurs in 37 – 78 % of stroke patients and increases risk of pneumonia 11-fold in patients with confirmed aspiration .
6-1	599-608	Dysphagia	abstract	new	coref	7-35
6-2	609-615	occurs	_	_	_	_
6-3	616-618	in	_	_	_	_
6-4	619-621	37	quantity	new	_	_
6-5	622-623	–	_	_	_	_
6-6	624-626	78	quantity[34]	new[34]	_	_
6-7	627-628	%	quantity[34]	new[34]	_	_
6-8	629-631	of	quantity[34]	new[34]	_	_
6-9	632-638	stroke	quantity[34]|event|person[36]	new[34]|giv|giv[36]	coref|coref	6-18[40_36]|7-14[46_0]
6-10	639-647	patients	quantity[34]|person[36]	new[34]|giv[36]	_	_
6-11	648-651	and	_	_	_	_
6-12	652-661	increases	_	_	_	_
6-13	662-666	risk	abstract[37]	new[37]	_	_
6-14	667-669	of	abstract[37]	new[37]	_	_
6-15	670-679	pneumonia	abstract[37]|abstract|abstract[39]	new[37]|giv|new[39]	coref	8-15
6-16	680-687	11-fold	abstract[37]|abstract[39]	new[37]|new[39]	_	_
6-17	688-690	in	abstract[37]|abstract[39]	new[37]|new[39]	_	_
6-18	691-699	patients	abstract[37]|abstract[39]|person[40]	new[37]|new[39]|giv[40]	coref	15-19[143_40]
6-19	700-704	with	abstract[37]|abstract[39]|person[40]	new[37]|new[39]|giv[40]	_	_
6-20	705-714	confirmed	abstract[37]|abstract[39]|person[40]|abstract[41]	new[37]|new[39]|giv[40]|giv[41]	coref	13-6[0_41]
6-21	715-725	aspiration	abstract[37]|abstract[39]|person[40]|abstract[41]	new[37]|new[39]|giv[40]|giv[41]	_	_
6-22	726-727	.	_	_	_	_

#Text=In the United Kingdom ( UK ) , national guidelines recommend people with acute stroke have their swallow screened within 4 h of hospital admission by a specifically trained healthcare professional and , if dysphagia is suspected , the person should have a specialist swallow assessment by a speech and language therapist ( SLT ) within 72 h of admission ( Supplementary Table S1 : Summary of Royal College of Physicians ( RCP ) Clinical Guideline for Stroke ) .
7-1	728-730	In	_	_	_	_
7-2	731-734	the	place[42]	new[42]	_	_
7-3	735-741	United	place[42]	new[42]	_	_
7-4	742-749	Kingdom	place[42]	new[42]	_	_
7-5	750-751	(	_	_	_	_
7-6	752-754	UK	place	new	_	_
7-7	755-756	)	_	_	_	_
7-8	757-758	,	_	_	_	_
7-9	759-767	national	abstract[44]	new[44]	_	_
7-10	768-778	guidelines	abstract[44]	new[44]	_	_
7-11	779-788	recommend	_	_	_	_
7-12	789-795	people	person[45]	new[45]	ana	7-17[0_45]
7-13	796-800	with	person[45]	new[45]	_	_
7-14	801-806	acute	person[45]|event[46]	new[45]|giv[46]	coref	7-78[0_46]
7-15	807-813	stroke	person[45]|event[46]	new[45]|giv[46]	_	_
7-16	814-818	have	_	_	_	_
7-17	819-824	their	person|animal[48]	giv|new[48]	coref	7-45[0_48]
7-18	825-832	swallow	animal[48]	new[48]	_	_
7-19	833-841	screened	_	_	_	_
7-20	842-848	within	_	_	_	_
7-21	849-850	4	quantity[49]	new[49]	_	_
7-22	851-852	h	quantity[49]	new[49]	_	_
7-23	853-855	of	quantity[49]	new[49]	_	_
7-24	856-864	hospital	quantity[49]|place|event[51]	new[49]|giv|new[51]	coref	7-60[0_51]
7-25	865-874	admission	quantity[49]|event[51]	new[49]|new[51]	_	_
7-26	875-877	by	quantity[49]|event[51]	new[49]|new[51]	_	_
7-27	878-879	a	quantity[49]|event[51]	new[49]|new[51]	_	_
7-28	880-892	specifically	quantity[49]|event[51]	new[49]|new[51]	_	_
7-29	893-900	trained	quantity[49]|event[51]	new[49]|new[51]	_	_
7-30	901-911	healthcare	quantity[49]|event[51]|organization	new[49]|new[51]|new	_	_
7-31	912-924	professional	quantity[49]|event[51]	new[49]|new[51]	_	_
7-32	925-928	and	_	_	_	_
7-33	929-930	,	_	_	_	_
7-34	931-933	if	_	_	_	_
7-35	934-943	dysphagia	abstract	giv	coref	15-21
7-36	944-946	is	_	_	_	_
7-37	947-956	suspected	_	_	_	_
7-38	957-958	,	_	_	_	_
7-39	959-962	the	person[54]	new[54]	_	_
7-40	963-969	person	person[54]	new[54]	_	_
7-41	970-976	should	_	_	_	_
7-42	977-981	have	_	_	_	_
7-43	982-983	a	abstract[56]	new[56]	coref	8-20[75_56]
7-44	984-994	specialist	abstract[56]	new[56]	_	_
7-45	995-1002	swallow	animal|abstract[56]	giv|new[56]	coref	9-24
7-46	1003-1013	assessment	abstract[56]	new[56]	_	_
7-47	1014-1016	by	abstract[56]	new[56]	_	_
7-48	1017-1018	a	abstract[56]|abstract[57]	new[56]|new[57]	_	_
7-49	1019-1025	speech	abstract[56]|abstract[57]	new[56]|new[57]	_	_
7-50	1026-1029	and	abstract[56]	new[56]	_	_
7-51	1030-1038	language	abstract[56]|abstract|person[59]	new[56]|new|new[59]	appos	7-54[0_59]
7-52	1039-1048	therapist	abstract[56]|person[59]	new[56]|new[59]	_	_
7-53	1049-1050	(	abstract[56]	new[56]	_	_
7-54	1051-1054	SLT	abstract[56]|person	new[56]|giv	_	_
7-55	1055-1056	)	abstract[56]	new[56]	_	_
7-56	1057-1063	within	abstract[56]	new[56]	_	_
7-57	1064-1066	72	abstract[56]|quantity[61]	new[56]|new[61]	_	_
7-58	1067-1068	h	abstract[56]|quantity[61]	new[56]|new[61]	_	_
7-59	1069-1071	of	abstract[56]|quantity[61]	new[56]|new[61]	_	_
7-60	1072-1081	admission	abstract[56]|quantity[61]|event	new[56]|new[61]|giv	_	_
7-61	1082-1083	(	_	_	_	_
7-62	1084-1097	Supplementary	abstract[63]	new[63]	_	_
7-63	1098-1103	Table	abstract[63]	new[63]	_	_
7-64	1104-1106	S1	_	_	_	_
7-65	1107-1108	:	_	_	_	_
7-66	1109-1116	Summary	abstract[64]	new[64]	_	_
7-67	1117-1119	of	abstract[64]	new[64]	_	_
7-68	1120-1125	Royal	abstract[64]|organization[65]	new[64]|new[65]	_	_
7-69	1126-1133	College	abstract[64]|organization[65]	new[64]|new[65]	_	_
7-70	1134-1136	of	abstract[64]|organization[65]	new[64]|new[65]	_	_
7-71	1137-1147	Physicians	abstract[64]|organization[65]|person	new[64]|new[65]|new	_	_
7-72	1148-1149	(	_	_	_	_
7-73	1150-1153	RCP	place	new	coref	11-2
7-74	1154-1155	)	_	_	_	_
7-75	1156-1164	Clinical	abstract[68]	new[68]	coref	11-1[100_68]
7-76	1165-1174	Guideline	abstract[68]	new[68]	_	_
7-77	1175-1178	for	abstract[68]	new[68]	_	_
7-78	1179-1185	Stroke	abstract[68]|abstract	new[68]|giv	coref	11-6
7-79	1186-1187	)	_	_	_	_
7-80	1188-1189	.	_	_	_	_

#Text=There is increasing evidence that early dysphagia screening is associated with reduced odds of SAP and that delays in SLT assessment increase pneumonia incidence by 1 % per day of delay .
8-1	1190-1195	There	_	_	_	_
8-2	1196-1198	is	_	_	_	_
8-3	1199-1209	increasing	_	_	_	_
8-4	1210-1218	evidence	abstract[70]	new[70]	coref	11-11[103_70]
8-5	1219-1223	that	abstract[70]	new[70]	_	_
8-6	1224-1229	early	abstract[70]|abstract[71]	new[70]|new[71]	coref	9-5[0_71]
8-7	1230-1239	dysphagia	abstract[70]|abstract[71]	new[70]|new[71]	_	_
8-8	1240-1249	screening	abstract[70]|abstract[71]	new[70]|new[71]	_	_
8-9	1250-1252	is	abstract[70]	new[70]	_	_
8-10	1253-1263	associated	abstract[70]	new[70]	_	_
8-11	1264-1268	with	abstract[70]	new[70]	_	_
8-12	1269-1276	reduced	abstract[70]|abstract[72]	new[70]|new[72]	_	_
8-13	1277-1281	odds	abstract[70]|abstract[72]	new[70]|new[72]	_	_
8-14	1282-1284	of	abstract[70]|abstract[72]	new[70]|new[72]	_	_
8-15	1285-1288	SAP	abstract[70]|abstract[72]|abstract	new[70]|new[72]|giv	coref	8-23
8-16	1289-1292	and	abstract[70]	new[70]	_	_
8-17	1293-1297	that	abstract[70]	new[70]	_	_
8-18	1298-1304	delays	abstract[70]	new[70]	_	_
8-19	1305-1307	in	_	_	_	_
8-20	1308-1311	SLT	abstract|abstract[75]	new|giv[75]	coref|coref	9-22[88_75]|12-7[115_0]
8-21	1312-1322	assessment	abstract[75]	giv[75]	_	_
8-22	1323-1331	increase	_	_	_	_
8-23	1332-1341	pneumonia	abstract|abstract[77]	giv|new[77]	coref	15-17
8-24	1342-1351	incidence	abstract[77]	new[77]	_	_
8-25	1352-1354	by	_	_	_	_
8-26	1355-1356	1	quantity[78]	new[78]	_	_
8-27	1357-1358	%	quantity[78]	new[78]	_	_
8-28	1359-1362	per	quantity[78]	new[78]	_	_
8-29	1363-1366	day	quantity[78]|time[79]	new[78]|new[79]	_	_
8-30	1367-1369	of	quantity[78]|time[79]	new[78]|new[79]	_	_
8-31	1370-1375	delay	quantity[78]|time[79]|abstract	new[78]|new[79]|new	_	_
8-32	1376-1377	.	_	_	_	_

#Text=The type of dysphagia screening protocol ( DSP ) used varies widely and there is limited information about the components of the specialist swallow assessment .
9-1	1378-1381	The	abstract[81]	new[81]	_	_
9-2	1382-1386	type	abstract[81]	new[81]	_	_
9-3	1387-1389	of	abstract[81]	new[81]	_	_
9-4	1390-1399	dysphagia	abstract[81]|abstract[83]	new[81]|new[83]	appos	9-8[0_83]
9-5	1400-1409	screening	abstract[81]|abstract|abstract[83]	new[81]|giv|new[83]	coref	10-1
9-6	1410-1418	protocol	abstract[81]|abstract[83]	new[81]|new[83]	_	_
9-7	1419-1420	(	_	_	_	_
9-8	1421-1424	DSP	abstract	giv	coref	11-14[105_0]
9-9	1425-1426	)	_	_	_	_
9-10	1427-1431	used	_	_	_	_
9-11	1432-1438	varies	_	_	_	_
9-12	1439-1445	widely	_	_	_	_
9-13	1446-1449	and	_	_	_	_
9-14	1450-1455	there	_	_	_	_
9-15	1456-1458	is	_	_	_	_
9-16	1459-1466	limited	abstract[85]	new[85]	_	_
9-17	1467-1478	information	abstract[85]	new[85]	_	_
9-18	1479-1484	about	abstract[85]	new[85]	_	_
9-19	1485-1488	the	abstract[85]|abstract[86]	new[85]|new[86]	_	_
9-20	1489-1499	components	abstract[85]|abstract[86]	new[85]|new[86]	_	_
9-21	1500-1502	of	abstract[85]|abstract[86]	new[85]|new[86]	_	_
9-22	1503-1506	the	abstract[85]|abstract[86]|abstract[88]	new[85]|new[86]|giv[88]	coref	12-3[114_88]
9-23	1507-1517	specialist	abstract[85]|abstract[86]|abstract[88]	new[85]|new[86]|giv[88]	_	_
9-24	1518-1525	swallow	abstract[85]|abstract[86]|animal|abstract[88]	new[85]|new[86]|giv|giv[88]	_	_
9-25	1526-1536	assessment	abstract[85]|abstract[86]|abstract[88]	new[85]|new[86]|giv[88]	_	_
9-26	1537-1538	.	_	_	_	_

#Text=Screening protocols can vary from informal screens to validated protocols that assess with water only and stepwise screens that provide separate evaluations for non-fluids and fluids .
10-1	1539-1548	Screening	abstract|abstract[90]	giv|new[90]	coref|coref	10-9[92_90]|19-6[180_0]
10-2	1549-1558	protocols	abstract[90]	new[90]	_	_
10-3	1559-1562	can	_	_	_	_
10-4	1563-1567	vary	_	_	_	_
10-5	1568-1572	from	_	_	_	_
10-6	1573-1581	informal	object[91]	new[91]	coref	10-15[94_91]
10-7	1582-1589	screens	object[91]	new[91]	_	_
10-8	1590-1592	to	object[91]	new[91]	_	_
10-9	1593-1602	validated	object[91]|abstract[92]	new[91]|giv[92]	coref	11-37[111_92]
10-10	1603-1612	protocols	object[91]|abstract[92]	new[91]|giv[92]	_	_
10-11	1613-1617	that	_	_	_	_
10-12	1618-1624	assess	_	_	_	_
10-13	1625-1629	with	_	_	_	_
10-14	1630-1635	water	substance	new	coref	11-22
10-15	1636-1640	only	object[94]	giv[94]	_	_
10-16	1641-1644	and	object[94]	giv[94]	_	_
10-17	1645-1653	stepwise	object[94]	giv[94]	_	_
10-18	1654-1661	screens	object[94]	giv[94]	_	_
10-19	1662-1666	that	_	_	_	_
10-20	1667-1674	provide	_	_	_	_
10-21	1675-1683	separate	abstract[95]	new[95]	coref	14-1[132_95]
10-22	1684-1695	evaluations	abstract[95]	new[95]	_	_
10-23	1696-1699	for	_	_	_	_
10-24	1700-1710	non-fluids	substance	new	_	_
10-25	1711-1714	and	_	_	_	_
10-26	1715-1721	fluids	substance	new	coref	12-17[119_0]
10-27	1722-1723	.	_	_	_	_

#Text=The RCP Clinical Guideline for Stroke state that there is good evidence that a multi-item DSP that includes at least a water test of 10 teaspoons and a lingual motor test is more accurate than screening protocols with a single item , but do not recommend a standardised screen .
11-1	1724-1727	The	abstract[100]	giv[100]	_	_
11-2	1728-1731	RCP	place|abstract[100]	giv|giv[100]	_	_
11-3	1732-1740	Clinical	substance|abstract[100]	new|giv[100]	_	_
11-4	1741-1750	Guideline	abstract[100]	giv[100]	_	_
11-5	1751-1754	for	abstract[100]	giv[100]	_	_
11-6	1755-1761	Stroke	abstract[100]|abstract|abstract[102]	giv[100]|giv|new[102]	coref	18-23[175_0]
11-7	1762-1767	state	abstract[100]|abstract[102]	giv[100]|new[102]	_	_
11-8	1768-1772	that	_	_	_	_
11-9	1773-1778	there	_	_	_	_
11-10	1779-1781	is	_	_	_	_
11-11	1782-1786	good	abstract[103]	giv[103]	coref	16-4[145_103]
11-12	1787-1795	evidence	abstract[103]	giv[103]	_	_
11-13	1796-1800	that	_	_	_	_
11-14	1801-1802	a	abstract[105]	giv[105]	_	_
11-15	1803-1813	multi-item	abstract|abstract[105]	new|giv[105]	_	_
11-16	1814-1817	DSP	abstract[105]	giv[105]	_	_
11-17	1818-1822	that	_	_	_	_
11-18	1823-1831	includes	_	_	_	_
11-19	1832-1834	at	_	_	_	_
11-20	1835-1840	least	abstract[107]	new[107]	_	_
11-21	1841-1842	a	abstract[107]	new[107]	_	_
11-22	1843-1848	water	substance|abstract[107]	giv|new[107]	_	_
11-23	1849-1853	test	abstract[107]	new[107]	_	_
11-24	1854-1856	of	abstract[107]	new[107]	_	_
11-25	1857-1859	10	abstract[107]|quantity[108]	new[107]|new[108]	_	_
11-26	1860-1869	teaspoons	abstract[107]|quantity[108]	new[107]|new[108]	_	_
11-27	1870-1873	and	abstract[107]	new[107]	_	_
11-28	1874-1875	a	abstract[107]|abstract[110]	new[107]|new[110]	_	_
11-29	1876-1883	lingual	abstract[107]|abstract[110]	new[107]|new[110]	_	_
11-30	1884-1889	motor	abstract[107]|object|abstract[110]	new[107]|new|new[110]	_	_
11-31	1890-1894	test	abstract[107]|abstract[110]	new[107]|new[110]	_	_
11-32	1895-1897	is	_	_	_	_
11-33	1898-1902	more	_	_	_	_
11-34	1903-1911	accurate	_	_	_	_
11-35	1912-1916	than	_	_	_	_
11-36	1917-1926	screening	_	_	_	_
11-37	1927-1936	protocols	abstract[111]	giv[111]	_	_
11-38	1937-1941	with	abstract[111]	giv[111]	_	_
11-39	1942-1943	a	abstract[111]|abstract[112]	giv[111]|new[112]	_	_
11-40	1944-1950	single	abstract[111]|abstract[112]	giv[111]|new[112]	_	_
11-41	1951-1955	item	abstract[111]|abstract[112]	giv[111]|new[112]	_	_
11-42	1956-1957	,	_	_	_	_
11-43	1958-1961	but	_	_	_	_
11-44	1962-1964	do	_	_	_	_
11-45	1965-1968	not	_	_	_	_
11-46	1969-1978	recommend	_	_	_	_
11-47	1979-1980	a	abstract[113]	new[113]	_	_
11-48	1981-1993	standardised	abstract[113]	new[113]	_	_
11-49	1994-2000	screen	abstract[113]	new[113]	_	_
11-50	2001-2002	.	_	_	_	_

#Text=Typically , a swallow assessment by a SLT comprises a cranial nerve examination , trials of different fluids and diet textures and compensatory strategies .
12-1	2003-2012	Typically	_	_	_	_
12-2	2013-2014	,	_	_	_	_
12-3	2015-2016	a	abstract[114]	giv[114]	coref	14-7[134_114]
12-4	2017-2024	swallow	abstract[114]	giv[114]	_	_
12-5	2025-2035	assessment	abstract[114]	giv[114]	_	_
12-6	2036-2038	by	abstract[114]	giv[114]	_	_
12-7	2039-2040	a	abstract[114]|abstract[115]	giv[114]|giv[115]	_	_
12-8	2041-2044	SLT	abstract[114]|abstract[115]	giv[114]|giv[115]	_	_
12-9	2045-2054	comprises	_	_	_	_
12-10	2055-2056	a	event[116]|abstract[117]	new[116]|new[117]	ana|coref	13-1[0_117]|13-11[126_116]
12-11	2057-2064	cranial	event[116]|abstract[117]	new[116]|new[117]	_	_
12-12	2065-2070	nerve	event[116]|abstract[117]	new[116]|new[117]	_	_
12-13	2071-2082	examination	event[116]|abstract[117]	new[116]|new[117]	_	_
12-14	2083-2084	,	abstract[117]	new[117]	_	_
12-15	2085-2091	trials	abstract[117]|abstract[118]	new[117]|new[118]	_	_
12-16	2092-2094	of	abstract[117]|abstract[118]	new[117]|new[118]	_	_
12-17	2095-2104	different	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
12-18	2105-2111	fluids	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
12-19	2112-2115	and	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
12-20	2116-2120	diet	abstract[117]|abstract[118]|substance[119]|object|abstract[121]	new[117]|new[118]|giv[119]|new|new[121]	_	_
12-21	2121-2129	textures	abstract[117]|abstract[118]|substance[119]|abstract[121]	new[117]|new[118]|giv[119]|new[121]	_	_
12-22	2130-2133	and	abstract[117]|abstract[118]|substance[119]	new[117]|new[118]|giv[119]	_	_
12-23	2134-2146	compensatory	abstract[117]|abstract[118]|substance[119]|abstract[122]	new[117]|new[118]|giv[119]|new[122]	_	_
12-24	2147-2157	strategies	abstract[117]|abstract[118]|substance[119]|abstract[122]	new[117]|new[118]|giv[119]|new[122]	_	_
12-25	2158-2159	.	_	_	_	_

#Text=Those suspected of risk of aspiration should be assessed for instrumental examination using techniques such as videofluoroscopic swallowing examination ( VFSE ) or fibreoptic endoscopic evaluation of swallowing ( FEES ) .
13-1	2160-2165	Those	abstract	giv	_	_
13-2	2166-2175	suspected	_	_	_	_
13-3	2176-2178	of	_	_	_	_
13-4	2179-2183	risk	abstract[124]	new[124]	_	_
13-5	2184-2186	of	abstract[124]	new[124]	_	_
13-6	2187-2197	aspiration	abstract[124]|abstract	new[124]|giv	_	_
13-7	2198-2204	should	_	_	_	_
13-8	2205-2207	be	_	_	_	_
13-9	2208-2216	assessed	_	_	_	_
13-10	2217-2220	for	_	_	_	_
13-11	2221-2233	instrumental	event[126]	giv[126]	coref	13-17[128_126]
13-12	2234-2245	examination	event[126]	giv[126]	_	_
13-13	2246-2251	using	_	_	_	_
13-14	2252-2262	techniques	abstract[127]	new[127]	_	_
13-15	2263-2267	such	abstract[127]	new[127]	_	_
13-16	2268-2270	as	abstract[127]	new[127]	_	_
13-17	2271-2288	videofluoroscopic	abstract[127]|event[128]	new[127]|giv[128]	_	_
13-18	2289-2299	swallowing	abstract[127]|event[128]	new[127]|giv[128]	_	_
13-19	2300-2311	examination	abstract[127]|event[128]	new[127]|giv[128]	_	_
13-20	2312-2313	(	_	_	_	_
13-21	2314-2318	VFSE	object	new	_	_
13-22	2319-2320	)	_	_	_	_
13-23	2321-2323	or	_	_	_	_
13-24	2324-2334	fibreoptic	abstract[130]	new[130]	_	_
13-25	2335-2345	endoscopic	abstract[130]	new[130]	_	_
13-26	2346-2356	evaluation	abstract[130]	new[130]	_	_
13-27	2357-2359	of	_	_	_	_
13-28	2360-2370	swallowing	_	_	_	_
13-29	2371-2372	(	_	_	_	_
13-30	2373-2377	FEES	abstract	new	_	_
13-31	2378-2379	)	_	_	_	_
13-32	2380-2381	.	_	_	_	_

#Text=These assessments provide direct imaging for assessment of the swallowing physiology and help to predict outcomes and treatment planning .
14-1	2382-2387	These	abstract[132]	giv[132]	_	_
14-2	2388-2399	assessments	abstract[132]	giv[132]	_	_
14-3	2400-2407	provide	_	_	_	_
14-4	2408-2414	direct	abstract[133]	new[133]	_	_
14-5	2415-2422	imaging	abstract[133]	new[133]	_	_
14-6	2423-2426	for	abstract[133]	new[133]	_	_
14-7	2427-2437	assessment	abstract[133]|abstract[134]	new[133]|giv[134]	coref	18-17[0_134]
14-8	2438-2440	of	abstract[133]|abstract[134]	new[133]|giv[134]	_	_
14-9	2441-2444	the	abstract[133]|abstract[134]|abstract[135]	new[133]|giv[134]|new[135]	_	_
14-10	2445-2455	swallowing	abstract[133]|abstract[134]|abstract[135]	new[133]|giv[134]|new[135]	_	_
14-11	2456-2466	physiology	abstract[133]|abstract[134]|abstract[135]	new[133]|giv[134]|new[135]	_	_
14-12	2467-2470	and	_	_	_	_
14-13	2471-2475	help	_	_	_	_
14-14	2476-2478	to	_	_	_	_
14-15	2479-2486	predict	_	_	_	_
14-16	2487-2495	outcomes	event[136]	giv[136]	_	_
14-17	2496-2499	and	event[136]	giv[136]	_	_
14-18	2500-2509	treatment	event[136]|event|event[138]	giv[136]|new|new[138]	coref	17-23[158_0]
14-19	2510-2518	planning	event[136]|event[138]	giv[136]|new[138]	_	_
14-20	2519-2520	.	_	_	_	_

#Text=A range of medical interventions and clinical processes may also be associated with the risk of SAP in patients with dysphagia .
15-1	2521-2522	A	_	_	_	_
15-2	2523-2528	range	_	_	_	_
15-3	2529-2531	of	_	_	_	_
15-4	2532-2539	medical	event[139]	new[139]	_	_
15-5	2540-2553	interventions	event[139]	new[139]	_	_
15-6	2554-2557	and	_	_	_	_
15-7	2558-2566	clinical	abstract[140]	new[140]	_	_
15-8	2567-2576	processes	abstract[140]	new[140]	_	_
15-9	2577-2580	may	_	_	_	_
15-10	2581-2585	also	_	_	_	_
15-11	2586-2588	be	_	_	_	_
15-12	2589-2599	associated	_	_	_	_
15-13	2600-2604	with	_	_	_	_
15-14	2605-2608	the	abstract[141]	new[141]	coref	16-24[152_141]
15-15	2609-2613	risk	abstract[141]	new[141]	_	_
15-16	2614-2616	of	abstract[141]	new[141]	_	_
15-17	2617-2620	SAP	abstract[141]|abstract	new[141]|giv	coref	16-27
15-18	2621-2623	in	abstract[141]	new[141]	_	_
15-19	2624-2632	patients	abstract[141]|person[143]	new[141]|giv[143]	coref	16-22[0_143]
15-20	2633-2637	with	abstract[141]|person[143]	new[141]|giv[143]	_	_
15-21	2638-2647	dysphagia	abstract[141]|person[143]|abstract	new[141]|giv[143]|giv	coref	16-18
15-22	2648-2649	.	_	_	_	_

#Text=There is emerging evidence for the use of preventative measures such as screening for stroke-induced immunosuppression and dysphagia , for identifying patients at high risk for SAP .
16-1	2650-2655	There	_	_	_	_
16-2	2656-2658	is	_	_	_	_
16-3	2659-2667	emerging	_	_	_	_
16-4	2668-2676	evidence	abstract[145]	giv[145]	_	_
16-5	2677-2680	for	abstract[145]	giv[145]	_	_
16-6	2681-2684	the	abstract[145]|abstract[146]	giv[145]|new[146]	_	_
16-7	2685-2688	use	abstract[145]|abstract[146]	giv[145]|new[146]	_	_
16-8	2689-2691	of	abstract[145]|abstract[146]	giv[145]|new[146]	_	_
16-9	2692-2704	preventative	abstract[145]|abstract[146]|abstract[147]	giv[145]|new[146]|new[147]	_	_
16-10	2705-2713	measures	abstract[145]|abstract[146]|abstract[147]	giv[145]|new[146]|new[147]	_	_
16-11	2714-2718	such	_	_	_	_
16-12	2719-2721	as	_	_	_	_
16-13	2722-2731	screening	_	_	_	_
16-14	2732-2735	for	_	_	_	_
16-15	2736-2750	stroke-induced	abstract[148]|abstract[149]	giv[148]|giv[149]	_	_
16-16	2751-2768	immunosuppression	abstract[148]|abstract[149]	giv[148]|giv[149]	_	_
16-17	2769-2772	and	abstract[149]	giv[149]	_	_
16-18	2773-2782	dysphagia	abstract[149]|abstract	giv[149]|giv	coref	17-41
16-19	2783-2784	,	_	_	_	_
16-20	2785-2788	for	_	_	_	_
16-21	2789-2800	identifying	_	_	_	_
16-22	2801-2809	patients	person	giv	coref	17-39[166_0]
16-23	2810-2812	at	_	_	_	_
16-24	2813-2817	high	abstract[152]	giv[152]	_	_
16-25	2818-2822	risk	abstract[152]	giv[152]	_	_
16-26	2823-2826	for	abstract[152]	giv[152]	_	_
16-27	2827-2830	SAP	abstract[152]|abstract	giv[152]|giv	coref	17-37[165_0]
16-28	2831-2832	.	_	_	_	_

#Text=Further studies are needed to test this and screening for oral aerobic Gram-negative bacteria as well as the need to evaluate if treatment with proton pump inhibitors and nasogastric tubes ( NGT ) are associated with SAP in patients with dysphagia .
17-1	2833-2840	Further	event[154]	new[154]	coref	18-10[0_154]
17-2	2841-2848	studies	event[154]	new[154]	_	_
17-3	2849-2852	are	_	_	_	_
17-4	2853-2859	needed	_	_	_	_
17-5	2860-2862	to	_	_	_	_
17-6	2863-2867	test	_	_	_	_
17-7	2868-2872	this	_	_	_	_
17-8	2873-2876	and	_	_	_	_
17-9	2877-2886	screening	_	_	_	_
17-10	2887-2890	for	_	_	_	_
17-11	2891-2895	oral	plant[156]	new[156]	_	_
17-12	2896-2903	aerobic	plant[156]	new[156]	_	_
17-13	2904-2917	Gram-negative	abstract|plant[156]	new|new[156]	_	_
17-14	2918-2926	bacteria	plant[156]	new[156]	_	_
17-15	2927-2929	as	_	_	_	_
17-16	2930-2934	well	_	_	_	_
17-17	2935-2937	as	_	_	_	_
17-18	2938-2941	the	abstract[157]	new[157]	_	_
17-19	2942-2946	need	abstract[157]	new[157]	_	_
17-20	2947-2949	to	_	_	_	_
17-21	2950-2958	evaluate	_	_	_	_
17-22	2959-2961	if	_	_	_	_
17-23	2962-2971	treatment	event[158]	giv[158]	_	_
17-24	2972-2976	with	event[158]	giv[158]	_	_
17-25	2977-2983	proton	event[158]|person|object[161]	giv[158]|new|new[161]	_	_
17-26	2984-2988	pump	event[158]|object|object[161]	giv[158]|new|new[161]	_	_
17-27	2989-2999	inhibitors	event[158]|object[161]	giv[158]|new[161]	_	_
17-28	3000-3003	and	event[158]	giv[158]	_	_
17-29	3004-3015	nasogastric	event[158]|abstract|object[163]	giv[158]|new|new[163]	_	_
17-30	3016-3021	tubes	event[158]|object[163]	giv[158]|new[163]	_	_
17-31	3022-3023	(	_	_	_	_
17-32	3024-3027	NGT	substance	new	_	_
17-33	3028-3029	)	_	_	_	_
17-34	3030-3033	are	_	_	_	_
17-35	3034-3044	associated	_	_	_	_
17-36	3045-3049	with	_	_	_	_
17-37	3050-3053	SAP	abstract[165]	giv[165]	coref	18-29[0_165]
17-38	3054-3056	in	abstract[165]	giv[165]	_	_
17-39	3057-3065	patients	abstract[165]|person[166]	giv[165]|giv[166]	coref	19-15[184_166]
17-40	3066-3070	with	abstract[165]|person[166]	giv[165]|giv[166]	_	_
17-41	3071-3080	dysphagia	abstract[165]|person[166]|abstract	giv[165]|giv[166]|giv	coref	18-21[174_0]
17-42	3081-3082	.	_	_	_	_

#Text=This study forms part of an over-arching series of studies aiming to explore whether variation in assessment and management of dysphagia in acute stroke affects the development of SAP .
18-1	3083-3087	This	abstract[168]	new[168]	coref	21-4[206_168]
18-2	3088-3093	study	abstract[168]	new[168]	_	_
18-3	3094-3099	forms	_	_	_	_
18-4	3100-3104	part	_	_	_	_
18-5	3105-3107	of	_	_	_	_
18-6	3108-3110	an	abstract[169]	new[169]	_	_
18-7	3111-3123	over-arching	abstract[169]	new[169]	_	_
18-8	3124-3130	series	abstract[169]	new[169]	_	_
18-9	3131-3133	of	abstract[169]	new[169]	_	_
18-10	3134-3141	studies	abstract[169]|event	new[169]|giv	_	_
18-11	3142-3148	aiming	_	_	_	_
18-12	3149-3151	to	_	_	_	_
18-13	3152-3159	explore	_	_	_	_
18-14	3160-3167	whether	_	_	_	_
18-15	3168-3177	variation	abstract[171]	new[171]	_	_
18-16	3178-3180	in	abstract[171]	new[171]	_	_
18-17	3181-3191	assessment	abstract[171]|abstract	new[171]|giv	coref	19-9
18-18	3192-3195	and	abstract[171]	new[171]	_	_
18-19	3196-3206	management	abstract[171]|organization[173]	new[171]|new[173]	_	_
18-20	3207-3209	of	abstract[171]|organization[173]	new[171]|new[173]	_	_
18-21	3210-3219	dysphagia	abstract[171]|organization[173]|abstract[174]	new[171]|new[173]|giv[174]	coref	21-23[0_174]
18-22	3220-3222	in	abstract[171]|organization[173]|abstract[174]	new[171]|new[173]|giv[174]	_	_
18-23	3223-3228	acute	abstract[171]|organization[173]|abstract[174]|event[175]	new[171]|new[173]|giv[174]|giv[175]	coref	19-15[0_175]
18-24	3229-3235	stroke	abstract[171]|organization[173]|abstract[174]|event[175]	new[171]|new[173]|giv[174]|giv[175]	_	_
18-25	3236-3243	affects	_	_	_	_
18-26	3244-3247	the	abstract[176]	new[176]	_	_
18-27	3248-3259	development	abstract[176]	new[176]	_	_
18-28	3260-3262	of	abstract[176]	new[176]	_	_
18-29	3263-3266	SAP	abstract[176]|abstract	new[176]|giv	coref	20-17
18-30	3267-3268	.	_	_	_	_

#Text=Interviews with staff responsible for dysphagia screening , assessment and or clinical management of stroke patients were undertaken as part of a mixed methods research design to inform the development of a national survey of hospitals registered in the Sentinel Stroke National Audit Programme ( SSNAP ) database .
19-1	3269-3279	Interviews	event[178]	new[178]	_	_
19-2	3280-3284	with	event[178]	new[178]	_	_
19-3	3285-3290	staff	event[178]|person	new[178]|new	_	_
19-4	3291-3302	responsible	event[178]	new[178]	_	_
19-5	3303-3306	for	_	_	_	_
19-6	3307-3316	dysphagia	abstract[180]	giv[180]	coref	21-18[0_180]
19-7	3317-3326	screening	abstract[180]	giv[180]	_	_
19-8	3327-3328	,	_	_	_	_
19-9	3329-3339	assessment	abstract	giv	_	_
19-10	3340-3343	and	_	_	_	_
19-11	3344-3346	or	_	_	_	_
19-12	3347-3355	clinical	person[182]	new[182]	_	_
19-13	3356-3366	management	person[182]	new[182]	_	_
19-14	3367-3369	of	person[182]	new[182]	_	_
19-15	3370-3376	stroke	person[182]|event|person[184]	new[182]|giv|giv[184]	coref|coref	19-41|21-21[0_184]
19-16	3377-3385	patients	person[182]|person[184]	new[182]|giv[184]	_	_
19-17	3386-3390	were	_	_	_	_
19-18	3391-3401	undertaken	_	_	_	_
19-19	3402-3404	as	_	_	_	_
19-20	3405-3409	part	_	_	_	_
19-21	3410-3412	of	_	_	_	_
19-22	3413-3414	a	abstract[187]	new[187]	_	_
19-23	3415-3420	mixed	abstract[187]	new[187]	_	_
19-24	3421-3428	methods	abstract|abstract[187]	new|new[187]	_	_
19-25	3429-3437	research	abstract|abstract[187]	new|new[187]	_	_
19-26	3438-3444	design	abstract[187]	new[187]	_	_
19-27	3445-3447	to	_	_	_	_
19-28	3448-3454	inform	_	_	_	_
19-29	3455-3458	the	abstract[188]	new[188]	_	_
19-30	3459-3470	development	abstract[188]	new[188]	_	_
19-31	3471-3473	of	abstract[188]	new[188]	_	_
19-32	3474-3475	a	abstract[188]|abstract[189]	new[188]|new[189]	coref	20-5[0_189]
19-33	3476-3484	national	abstract[188]|abstract[189]	new[188]|new[189]	_	_
19-34	3485-3491	survey	abstract[188]|abstract[189]	new[188]|new[189]	_	_
19-35	3492-3494	of	abstract[188]|abstract[189]	new[188]|new[189]	_	_
19-36	3495-3504	hospitals	abstract[188]|abstract[189]|organization	new[188]|new[189]|new	_	_
19-37	3505-3515	registered	_	_	_	_
19-38	3516-3518	in	_	_	_	_
19-39	3519-3522	the	abstract[194]	new[194]	_	_
19-40	3523-3531	Sentinel	organization|abstract[194]	new|new[194]	_	_
19-41	3532-3538	Stroke	abstract|abstract[194]	giv|new[194]	_	_
19-42	3539-3547	National	event[193]|abstract[194]	new[193]|new[194]	coref	21-15[0_193]
19-43	3548-3553	Audit	event[193]|abstract[194]	new[193]|new[194]	_	_
19-44	3554-3563	Programme	abstract[194]	new[194]	_	_
19-45	3564-3565	(	_	_	_	_
19-46	3566-3571	SSNAP	organization	new	coref	21-34
19-47	3572-3573	)	_	_	_	_
19-48	3574-3582	database	object	new	coref	20-8[200_0]
19-49	3583-3584	.	_	_	_	_

#Text=Statistical analysis of the survey responses with the database will highlight barriers and facilitators for reducing SAP .
20-1	3585-3596	Statistical	abstract[197]	new[197]	_	_
20-2	3597-3605	analysis	abstract[197]	new[197]	_	_
20-3	3606-3608	of	abstract[197]	new[197]	_	_
20-4	3609-3612	the	abstract[197]|abstract[199]	new[197]|new[199]	_	_
20-5	3613-3619	survey	abstract[197]|abstract|abstract[199]	new[197]|giv|new[199]	_	_
20-6	3620-3629	responses	abstract[197]|abstract[199]	new[197]|new[199]	_	_
20-7	3630-3634	with	abstract[197]|abstract[199]	new[197]|new[199]	_	_
20-8	3635-3638	the	abstract[197]|abstract[199]|object[200]	new[197]|new[199]|giv[200]	_	_
20-9	3639-3647	database	abstract[197]|abstract[199]|object[200]	new[197]|new[199]|giv[200]	_	_
20-10	3648-3652	will	_	_	_	_
20-11	3653-3662	highlight	_	_	_	_
20-12	3663-3671	barriers	abstract	new	_	_
20-13	3672-3675	and	_	_	_	_
20-14	3676-3688	facilitators	abstract	new	_	_
20-15	3689-3692	for	_	_	_	_
20-16	3693-3701	reducing	_	_	_	_
20-17	3702-3705	SAP	abstract	giv	_	_
20-18	3706-3707	.	_	_	_	_

#Text=The aim of the interview study was to explore beyond the 4-h and 72-h audit criteria for screening and assessing patients for dysphagia to give a more rounded picture of care beyond the SSNAP performance indicators .
21-1	3708-3711	The	abstract[204]	new[204]	_	_
21-2	3712-3715	aim	abstract[204]	new[204]	_	_
21-3	3716-3718	of	abstract[204]	new[204]	_	_
21-4	3719-3722	the	abstract[204]|abstract[206]	new[204]|giv[206]	_	_
21-5	3723-3732	interview	abstract[204]|event|abstract[206]	new[204]|new|giv[206]	_	_
21-6	3733-3738	study	abstract[204]|abstract[206]	new[204]|giv[206]	_	_
21-7	3739-3742	was	_	_	_	_
21-8	3743-3745	to	_	_	_	_
21-9	3746-3753	explore	_	_	_	_
21-10	3754-3760	beyond	_	_	_	_
21-11	3761-3764	the	abstract[207]	new[207]	_	_
21-12	3765-3768	4-h	abstract[207]	new[207]	_	_
21-13	3769-3772	and	_	_	_	_
21-14	3773-3777	72-h	time|abstract[210]	new|new[210]	_	_
21-15	3778-3783	audit	event|abstract[210]	giv|new[210]	_	_
21-16	3784-3792	criteria	abstract[210]	new[210]	_	_
21-17	3793-3796	for	_	_	_	_
21-18	3797-3806	screening	abstract	giv	_	_
21-19	3807-3810	and	_	_	_	_
21-20	3811-3820	assessing	_	_	_	_
21-21	3821-3829	patients	person	giv	_	_
21-22	3830-3833	for	_	_	_	_
21-23	3834-3843	dysphagia	abstract	giv	_	_
21-24	3844-3846	to	_	_	_	_
21-25	3847-3851	give	_	_	_	_
21-26	3852-3853	a	abstract[214]	new[214]	_	_
21-27	3854-3858	more	abstract[214]	new[214]	_	_
21-28	3859-3866	rounded	abstract[214]	new[214]	_	_
21-29	3867-3874	picture	abstract[214]	new[214]	_	_
21-30	3875-3877	of	abstract[214]	new[214]	_	_
21-31	3878-3882	care	abstract[214]|abstract[215]	new[214]|new[215]	_	_
21-32	3883-3889	beyond	abstract[214]|abstract[215]	new[214]|new[215]	_	_
21-33	3890-3893	the	abstract[214]|abstract[215]|abstract[218]	new[214]|new[215]|new[218]	_	_
21-34	3894-3899	SSNAP	abstract[214]|abstract[215]|abstract|abstract[218]	new[214]|new[215]|giv|new[218]	_	_
21-35	3900-3911	performance	abstract[214]|abstract[215]|abstract|abstract[218]	new[214]|new[215]|new|new[218]	_	_
21-36	3912-3922	indicators	abstract[214]|abstract[215]|abstract[218]	new[214]|new[215]|new[218]	_	_
21-37	3923-3924	.	_	_	_	_
